Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report

<p>Abstract</p> <p>Introduction</p> <p>Auron Misheil Therapy was developed based on similarities between carcinogenesis and inflammation. Auron Misheil Therapy is a combination of natural and synthetic compounds, including anti-inflammatory drugs and insulin, expected to exhibit synergistic effects.</p> <p>Case presentation</p> <p>Here, we report the case of a 78-year-old Caucasian male patient who presented with multifocal hepatocellular carcinoma and chronic hepatitis C virus infection. Over a four-year period our patient was treated with radiofrequency ablation and transarterial chemoembolization. After these treatments there was tumor progression, with new hyperperfused lesions without evidence of extrahepatic tumor involvement. Our patient refused sorafenib therapy. Therefore, he received twice daily intramuscular injections of Auron Misheil Therapy on an outpatient basis for two months. Partial remission of the hepatic lesions was observed eight weeks after the start of treatment, and confirmed four weeks later. Unfortunately, at that time our patient refused therapy due to dizziness. During follow-up two target lesions remained stable, but one lesion increased in size. At the latest follow-up, one year later, there was still tumor control.</p> <p>Conclusion</p> <p>While the mechanisms underlying the antitumor effects of Auron Misheil Therapy are not fully understood, stable disease and remissions have been observed in different types of tumors, including hepatocellular carcinoma.</p

PBX1 is dispensable for neural commitment of RA-treated murine ES cells

Experimentation with PBX1 knockout mice has shown that PBX1 is necessary for early embryogenesis. Despite broad insight into PBX1 function, little is known about the underlying target gene regulation. Utilizing the Cre–loxP system, we targeted a functionally important part of the homeodomain of PBX1 through homozygous deletion of exon-6 and flanking intronic regions leading to exon 7 skipping in embryonic stem (ES) cells. We induced in vitro differentiation of wild-type and PBX1 mutant ES cells by aggregation and retinoic acid (RA) treatment and compared their profiles of gene expression at the ninth day post-reattachment to adhesive media. Our results indicate that PBX1 interactions with HOX proteins and DNA are dispensable for RA-induced ability of ES to express neural genes and point to a possible involvement of PBX1 in the regulation of imprinted genes

Sharing Project Experience through Case-based Reasoning

AbstractToday, most knowledge-based companies organize work in projects. Due to different reasons knowledge gained in projects is not documented and shared in an appropriate manner resulting in the problem that critical knowledge is lost. We propose case-based storage of relevant knowledge and an appropriate reasoning about this knowledge to support organizations in new projects. In order to achieve this objective, we have analyzed which kind of critical knowledge is gained in projects or other way round, which missing knowledge results in the failing of projects. A case is a pre-defined knowledge structure filled out by potentially different stakeholders of the project. After the first planning of a new project, if the project characteristics are entered, case-based reasoning is used to find similar old projects and derive from them additional attributes and to make potential risks visible. This is useful to better estimate the effort of a project, the required human competences and the required communication between stakeholders. This knowledge transfer can support also other phases of a project such as scheduling activities. In a closing phase, individual problems solved in the project can be documented as a kind of lessons-learned attempt